Immunovaccine Announces 2010 Second Quarter Results

By The Associated Press Friday, August 27, 2024

newsvine diigo google
slashdot
Share
Loading...

http://www.imvaccine.com/ () —

Immunovaccine Inc. (TSX VENTURE: IMV), a clinical stage vaccine company, today announced its operational and financial results for the second quarter ended June 30, 2024 ("Q2 Fiscal 2010").

"In July, we signed a deal with Merck KGaA to add DPX-Survivac to our pipeline," said Dr. Randal Chase, President and CEO of Immunovaccine. "This gives us two clinical stage cancer vaccines in active development. Over the coming months our focus will remain on our ongoing Phase I study with DPX-0907 in patients with breast, prostate or ovarian cancer. At the same time, we will begin the formulation and optimization process of combining Survivac and DepoVax with the goal of moving to the clinic as soon as possible. We also look forward to leveraging our clinical work to accelerate our business development efforts with additional licensing agreements and research collaborations."

Financial Results for three months ended June 30, 2024 -- Reported a consolidated net loss of $1,802,000 in Q2 Fiscal 2010 compared to a net loss $914,000 during the three month period ended June 30, 2009. Of this increase, approximately $298,000 related to the increased expenses associated with the Phase I clinical trial, $238,000 related to increased business development expenditures and $115,000 related to an increase in non-cash stock-based compensation. The remaining increase of $237,000 related primarily to increased administrative and regulatory costs associated with being a reporting issuer. -- Reported revenues in Q2 Fiscal 2010 of $6,000 compared to no revenues in the first quarter of 2009. These revenues were generated through the Company's animal health activities. -- Ended June 30, 2024 with cash and equivalents of approximately $5.7 million.

Results from operations

Overall operating expenses increased by $844,000 (85 during Q2 Fiscal 2010 compared to the three month period ended June 30, 2009. During the six month period ending June 30, 2024 total operating expenses increased by $1,339,000 (65%) compared to the six month period ended June 30, 2009. The higher operating expenses are mainly a result of the Company's research and development expenses associated with the DPX-0907 Phase I clinical trial, as well as advancing preclinical studies, business development activities, and expenses associated with now being a publicly traded company.

Total research and development (R&D) expenses of $854,000 for Q2 Fiscal 2010 represented a $301,000 (54 increase over the three month period ended June 30, 2009. Total R&D expenses of $1,621,000 incurred during the six month period ended June 30, 2024 represented an increase of $377,000 (30%) over the six month period ended June 30, 2009. The largest component of R&D expenses, $632,000, was directly associated with the continuation of the Phase I clinical trial for the Company's therapeutic cancer vaccine, DPX-0907.

General and administrative (G&A) expenses of $500,000 represented 27% of total expenses for Q2 Fiscal 2010 compared to $310,000 (31% of total expenses) for the three month period ended June 30, 2009. G&A expenses of $889,000 represented 26% of total expenses for the six month period ended June 30, 2024 compared to $597,000 (29% of total expenses) for the six month period ended June 30, 2009. Overall increased G&A expenses are due primarily to increased professional services and regulatory expenses associated with being a reporting issuer.

The Company continued to expand its business development (BD) activities during Q2 Fiscal 2010. Total BD expenses of $339,000 represented an increase of $238,000 compared to the three month period ended June 30, 2009. Total BD expenses for the six month period ended June 30, 2024 were $522,000 and represented an increase of $328,000, compared to the six month period ended June 30, 2009. Included in this increase were $156,000 in legal fees and $63,000 in consulting fees directly related to expanding the Company's vaccine pipeline, leading to the recent completion of both the Merck KGaA and Oncothyreon agreements.

Investment tax credits decreased to $50,000 for the total amount recorded for the six month period ended June 30, 2010, from approximately $155,000 during the six month period ended June 30, 2009. The decrease is a result of becoming a public corporation on October 1, 2009, pursuant to which to which the Company no longer qualifies for the refundable federal portion of the investment tax credits.

Non-cash stock-based compensation increased by $342,000 to $382,000 during the six month period ended June 30, 2024 compared to the six month period ended June 30, 2009. The increase was due primarily to the increased number of presently vesting options when compared to the six month period ended June 30, 2009, when there were a smaller number of unvested options outstanding.

As of August 27, 2010, issued and outstanding common shares are 45,555,479, with 3,259,687 stock options and 431,573 broker warrants outstanding. The outstanding stock options have a weighted average exercise price of $0.86 per share, and a weighted average remaining term of 5.3 years. The outstanding warrants expire on September 30, 2010 and have an exercise price of $0.70 per share.

Cash and cash equivalents

At June 30, 2010, the Company had cash and cash equivalents of $5,718,000, as compared to cash and cash equivalents of $6,866,000 at March 31, 2024 and $7,777,000 at December 31, 2009. At June 30, 2010, the Company had working capital of $6,311,000, as compared to working capital of $7,639,000 at March 31, 2024 and $8,326,000 at December 31, 2009.

The "cash burn rate" of the Company (defined as net loss for the period adjusted for non-cash transactions including amortization, stock-based compensation and shares issued for professional services) is forecasted to increase slightly due to the continuation of the Phase I clinical trial, and be in the range of $1.5 million to $1.7 million per quarter, on average, during Fiscal 2010. At June 30, 2010, the Company had cash resources of approximately $5.7 million and identified additional potential cash resources of $1.5 million. Management is of the belief that this provides the Company with sufficient funds to execute the strategy of completing the DPX-0907 Phase I trial while maintaining adequate working capital until the third quarter of 2011 as there are discretionary expenditures within the current cash forecast which would be reduced in the event that the identified potential sources of cash are not realized or receipt is delayed. The Company continually reassesses the adequacy of its cash resources since should either positive research results be obtained from existing research projects and/or potential collaboration opportunities identified, then additional funding may be required.

On August 11, 2010, the Company announced that it had filed a preliminary short form prospectus in connection with a marketed offering of Units of the Company (the "Offering"). Each Unit will consist of one common share of the Company and one-half of one common share purchase warrant (the "Warrant"). Each whole Warrant will entitle the holder to acquire one common share of the Company upon payment of the exercise price for a period of 36 months following the closing of the Offering. The price of the Units will be determined in the context of the market, with final pricing, determination of the number of Units to be sold pursuant to the Offering, and the exercise price and terms of the Warrants will be disclosed immediately prior to the filing of the final short form prospectus in respect of the Offering. The Offering is expected to close in September 2010.

On July 12, 2010, the Corporation announced that it had entered into an agreement with Merck KGaA to in-license EMD 640744, an investigational therapeutic survivin-based cancer vaccine, known as DPX-Survivac, designed to target multiple solid tumors and hematological malignancies. With the proceeds of the Offering, the Company intends to complete a Phase I study of DPX-Survivac. The Company intends to conduct most of its research activities using its own resources while utilizing third party subcontractors for the manufacture of clinical grade batches of the vaccine and to conduct clinical trials. The remaining proceeds will be used for general supporting research and development and general corporate and working capital purposes.

Recent Developments and Outlook

Immunovaccine continues to execute its business strategy and is actively pursuing additional collaborations and licensing deals. The Company's lead product DPX-0907, a therapeutic cancer vaccine, is on track to complete a Phase I clinical trial in 2011. With the recent acquisition of the Survivin-based vaccine from Merck KGaA, the Company is prioritizing the development of DPX-Survivac. The Survivin protein antigen has been ranked by the National Cancer Institute as a promising antigen because it is over-expressed in common cancers, such as melanoma, prostate, pancreatic, colorectal and multiple myeloma and virtually undetected in healthy tissue. Immunovaccine will further enhance DPX-Survivac by formulating it in its DepoVax delivery system, and completing the necessary preclinical work to take it into further clinical studies.

During Q2 Fiscal 2010 the Company also furthered its efforts to raise awareness of its technology and identify additional partnerships. Key achievements include: -- On April 5, 2010, the Company announced the publication of its DPX-0907 preclinical study comparing the Company's DepoVax vaccine delivery platform to a standard vaccine formulation used in the clinic today to deliver peptide antigens. The study shows that the DepoVax platform promotes stronger antigen specific immune responses and unlike the control vaccine, the DepoVax formulation does not induce problematic immune regulatory responses. -- On April 12, 2010, the Company signed a collaborative research agreement with the Dana-Farber Cancer Institute, a principal teaching affiliate of the Harvard Medical School. This research involves formulating Dana- Farber's HIV protein antigens in the Company's DepoVax vaccine delivery platform to establish whether it will induce a stronger immune response. -- On May 12, 2010, Mr. Paul Kirkconnell was elected to the Board of Directors. -- On June 7, 2010, the Company announced that it had signed a collaborative research agreement with Vaxil BioTherapeutics, an Israel- based company, to explore the efficacy of Vaxil's cancer antigens in the Company's DepoVax vaccine platform. -- On June 9, 2010, the Company announced the appointment of Keith Abriel, CA, CFA, as acting Chief Financial Officer, with immediate effect, following the departure of Chief Financial Officer, Mr. Gary Dodge, CA on June 7, 2010. Mr. Abriel will fulfill the role of acting Chief Financial Officer until a permanent appointment is made. -- On June 29, 2010, the Company announced that it had signed a research agreement with Oncothyreon Inc. a company based in Seattle, to formulate Oncothyreon's ONT-10, a therapeutic vaccine product candidate, in the Company's DepoVax vaccine platform for preclinical testing. -- Immunovaccine also announced, on July 12, 2010, that it had entered into an agreement with Merck KGaA to in-license EMD 640744, an investigational therapeutic survivin-based cancer vaccine. In acquiring this novel vaccine, the Company intends to build on the current on-going Phase I study for EMD 640744 by formulating DPX-Survivac in its DepoVax vaccine platform. The license agreement grants the Company exclusive worldwide rights, under issued patents and patent applications, to develop and commercialize DPX-Survivac for multiple cancer indications. Under the terms, the Company will pay Merck KGaA success-based milestone payments and royalties as a percentage of product sales. Merck KGaA, based in Darmstadt, Germany, is a global pharmaceutical and chemical company with total revenues of approximately EUR 7.7 billion in 2009 and approximately 33,600 employees in 64 countries according to its public filings. -- On July 29, 2010, the Company announced that Mr. Albert Scardino joined its Board of Directors. -- Immunovaccine also announces the resignation of Mr. Brian Lowe as Vice President and Corporate Secretary, effective immediately, in order to devote his full-time energies to his other businesses. Mr. Lowe, a Co- Founder of the Company, will continue to assist the Company as a consultant and remains committed to the continued and future success of Immunovaccine.

The Company's unaudited consolidated financial statements for Q2 Fiscal 2010 and the management discussion and analysis are available at www.sedar.com (http://www.sedar.com) .

Immunovaccine Inc. (TSX VENTURE: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax vaccine delivery technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com (http://www.imvaccine.com)

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Microplate Reader Test Plates Ensure Reliable Microplate Reader Operation

Aug 20

Use of a certified test plate can help to increase efficiency when calibrating microplate readers.

Automated Imaging Assisted Cell Line Development

Aug 19

Improve titer, quality and speed in cell line development.

New Frontiers: The Changing World of Biospecimen Collection and Management

Jul 30

The growth of biomarker research and personalized medicine requires more unified and large-scale software systems to track biological materials.

Optical Imaging in Stem Cell Research

Jun 1

Developing sensitive, non-invasive technologies to monitor engraftment in vivo is essential to accelerate the clinical implementation of cell therapies.

Step up to the MIQE

Mar 30

Over the years, polymerase chain reaction (PCR) has evolved into a readily automated, high throughput quantitative technology. Real-time quantitative PCR (qPCR) has become the industry standard for the detection and quantification of nucleic acids for multiple application, including quantification of RNA levels. But a lack of consensus among researchers on how to best perform and interpret qPCR experiments presents a major hurdle for advancement of the technology. This problem is exacerbated by insufficient experimental detail in published work, which impedes the ability of others to accurately evaluate or replicate reported results.

Fast Optimization of a Multiplex Influenza Identification Panel Using a Thermal Gradient

Mar 30

The year 2009 was marked by the emergence of a novel influenza A (H1N1) virus that infects humans. There is a need to identify the different strains of influenza virus for purposes of monitoring the H1N1 strain pandemic and for other epidemiological and scientific purposes.

Advantages of Monolithic Laser Combiner Technology in Confocal Microscopy Systems

Jan 6

Fluorescence microscopy techniques require a reliable light source at the desired wavelength or wavelengths, with minimal downtime for maintenance and alignment. Lasers are a popular light source, although the alignment and upkeep of laser combiners is a time-consuming prospect for many users.

Size-Exclusion Chromatography for Purification of Biomolecules

Dec 2 2009

Size-exclusion chromatography (SEC) is a popular method to separate biomolecules based on their size. Primarily, it is applied to the separation of biopolymers such as proteins and nucleic acids, i.e. water-soluble polymers.

Using the Tecan Genesis Workstation to Automate a Cytometric Bead Array (CBA) Immunoassay

Mar 11

The poster describe the process involved in automating a Cytometric Bead Array (CBA) immunoassay developed to measure relative concentrations of serum antibodies against Tetanus (TT), Sperm Whale Myoglobin (SWM) and Keyhole Limpet Hemocyanin (KLH) in KLH-immunized volunteers.

Ensuring Quality in Assays Performed with Automated Liquid Handlers

Feb 2

The focus of this presentation is to highlight the need of ensuring quality in important assays performed with automated liquid handlers. Nearly all assays performed within a laboratory are volume-dependent. In turn, all concentrations of biological and chemical components in these assays, as well as the associated dilution protocols, are volume-dependent. Because analyte concentration is volume-dependent, an assay’s results might be falsely interpreted if liquid handler variability and inaccuracies are unknown or if the system(s) go unchecked for a long period.

Inkjet System for Protein Crystallography

Feb 1

X-ray crystallography is used routinely by scientists to obtain the three dimensional structure of a biological molecule of interest.Such information can be used to determine how a pharmaceutical interacts with a protein target and what changes might improve functionality. However, the crystallization of macromolecules still remains a serious hindrance in structural determination despite impressive advances in screening methods and technologies.

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Attention Deficit & Hyperactivity in a Drosophila Memory Mutant

Nov 9 2009

Action selection is modulated by external stimuli either directly or via memory retrieval. In a constantly changing environment, animals have evolved attention-like processes to effectively filter the incoming sensory stream. These attention-like processes, in turn, are modulated by memory. The neurobiological nature of how attention, action selection and memory are inter-connected is unknown. We describe here new phenotypes of the memory mutant radish in the fruit fly Drosophila.

Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites.

3 hours ago

ABSTRACT: MirSVR is a new machine learning method for ranking microRNA target sites by a down-regulation score. The algorithm trains a regression model on sequence and contextual features extracted from miRanda-predicted target sites. In a large-scale...

Genomic acquisition of a capsular polysaccharide virulence cluster by non-pathogenic Burkholderia isolates.

3 hours ago

ABSTRACT: BACKGROUND: Burkholderia thailandensis is a non-pathogenic environmental saprophyte closely related to Burkholderia pseudomallei, the causative agent of the often fatal animal and human disease melioidosis. To study B. thailandensis genomic variation,...

Construction of a large extracellular protein interaction network and its resolution by spatiotemporal expression profiling.

4 hours ago

Extracellular interactions involving both secreted and membrane-tethered receptor proteins are essential to initiate signaling pathways that orchestrate cellular behaviors within biological systems. Due to the biochemical properties of these proteins and their...

Sentinel Node Biopsy in Squamous-Cell Carcinoma of the Anal Canal.

5 hours ago

BACKGROUND: Radiochemotherapy is the standard treatment for patients with carcinoma of the anal canal. Therefore, a surgical specimen is not usually obtained. Inguinal lymph node metastases cannot be accurately predicted by either clinical examination or imaging...

Prokariotic Cell Collection in Denmark

Nov 6 2009

I would like to know about a prokariotic cell collection in Denmark. Is there a cell bank in this country? I need a Lactobacillus strain for a fermentation assay and this information about the bank is very helpful for me.

Request for Entries

Oct 16 2009

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Viewing SureFocus Slides

Jun 11

A demonstration of SureFocus Microscope Slides in the review of AFB Smears. SureFocus Slides are a patent-pending breakthrough in tuberculosis detection, as their fluorescent staining circle remains visible during review, Fluorescence Microscopy.

Podcasts:

Allen Institute for Brain Research

Allen Institute for Brain Research

Oct 14 2009

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.

Information: